Tango Therapeutics, Inc.

NASDAQ:TNGX

1.86 (USD) • At close March 13, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 4.11711.60719.8756.4715.43110.73214.5985.7666.4116.925.7715.7585.7166.78718.1536.3869.142-11.2615.0644.711
Cost of Revenue 000.6320.6250.6170.6131.5081.4581.4521.220.6860.6721.63421.92319.0791515.06312.97711.12910.822
Gross Profit 4.11711.60719.2435.8464.81410.11913.094.3084.9595.75.0855.088-15.918-15.136-0.926-8.614-5.921-24.238-6.065-6.111
Gross Profit Ratio 110.9680.9030.8860.9430.8970.7470.7740.8240.8810.884-2.785-2.23-0.051-1.349-0.6482.152-1.198-1.297
Reseach & Development Expenses 33.93733.26338.65438.06531.33927.14928.67128.03929.09128.74423.74124.3321.63421.92319.0791515.06312.97711.12910.822
General & Administrative Expenses 11.0911.22210.77310.6619.1059.2099.1748.0137.8878.0997.2326.8076.0664.4333.633.4673.0162.5182.3781.953
Selling & Marketing Expenses 00-0.632-0.6250000000000000000
SG&A 11.0911.22210.14110.0369.1059.2099.1748.0137.8878.0997.2326.8076.0664.4333.633.4673.0162.5182.3781.953
Other Expenses 001.9952.1842.0611.5142.6012.2781.5580.5230.05-0.0470.115-0.05-0.062-0.0550.0020.00400
Operating Expenses 45.02744.48548.79548.10140.44436.35837.84536.05236.97836.84330.97331.13727.726.35622.70918.46718.07915.4952.3541.863
Operating Income -40.91-32.878-29.552-42.255-35.013-25.626-23.247-30.286-30.567-29.923-25.202-24.99-21.984-19.569-4.556-12.081-8.937-26.756-8.443-8.064
Operating Income Ratio -9.937-2.833-1.487-6.53-6.447-2.388-1.592-5.253-4.768-4.324-4.367-4.34-3.846-2.883-0.251-1.892-0.9782.376-1.667-1.712
Total Other Income Expenses Net 3.2893.7654.0664.3814.2973.3862.6012.2781.5580.8730.3470.1710.1150.0410.0420.0490.073-0.0460.0510.15
Income Before Tax -37.621-29.113-25.486-37.874-30.716-22.24-20.646-28.008-29.009-29.05-24.855-25.208-21.869-19.528-4.514-12.032-8.864-26.802-8.392-7.914
Income Before Tax Ratio -9.138-2.508-1.282-5.853-5.656-2.072-1.414-4.857-4.525-4.198-4.307-4.378-3.826-2.877-0.249-1.884-0.972.38-1.657-1.68
Income Tax Expense 0.0490.0540.0650.040.0470.0230.064-2.2780.051-0.8730.003-0.1710.1770.062-0.0210.07400.0500
Net Income -37.67-29.167-25.551-37.914-30.763-22.263-20.71-25.73-29.06-28.177-24.858-25.037-22.046-19.59-4.493-12.106-8.864-26.802-8.392-7.914
Net Income Ratio -9.15-2.513-1.286-5.859-5.664-2.074-1.419-4.462-4.533-4.072-4.307-4.348-3.857-2.886-0.248-1.896-0.972.38-1.657-1.68
EPS -0.34-0.27-0.24-0.35-0.32-0.23-0.23-0.29-0.33-0.32-0.28-0.29-0.25-0.28-0.051-0.14-0.53-0.31-0.75-0.74
EPS Diluted -0.34-0.27-0.24-0.35-0.32-0.23-0.23-0.29-0.33-0.32-0.28-0.29-0.25-0.28-0.051-0.14-0.42-0.31-0.75-0.74
EBITDA -40.29-32.256-28.92-41.63-34.396-25.013-22.643-29.705-29.997-29.506-24.89-25.07-21.728-19.344-4.344-11.877-8.746-26.57-8.266-7.9
EBITDA Ratio -9.786-2.779-1.455-6.433-6.333-2.331-1.592-5.253-4.768-4.264-4.367-4.408-3.846-2.85-0.251-1.86-0.9572.376-1.632-1.677